Related references
Note: Only part of the references are listed.Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection
Chloe O. C. Orkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression
Susan Swindells et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
2840. Long-term Efficacy, Safety, and Durability of CAB and RPV as Two Drug Oral Maintenance Therapy: LATTE Week 312 Results
David Margolis et al.
Open Forum Infectious Diseases (2019)
In Vitro Antiviral Activity of Cabotegravir against HIV-2
Robert A. Smith et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Efficacies of Cabotegravir and Bictegravir against drug-resistant HIV-1 integrase mutants
Steven J. Smith et al.
RETROVIROLOGY (2018)
Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial
David A. Margolis et al.
LANCET (2017)
Effect of Rifampin on the Single-Dose Pharmacokinetics of Oral Cabotegravir in Healthy Subjects
S. L. Ford et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Lack of effect of oral cabotegravir on the pharmacokinetics of a levonorgestrel/ethinyl oestradiol-containing oral contraceptive in healthy adult women
Christine Trezza et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Effect of Cabotegravir on Cardiac Repolarization in Healthy Subjects
Yu Lou et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2016)
Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial
David A. Margolis et al.
LANCET INFECTIOUS DISEASES (2015)
Pharmacokinetics, Safety, and Tolerability With Repeat Doses of GSK1265744 and Rilpivirine (TMC278) Long-Acting Nanosuspensions in Healthy Adults
William Spreen et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2014)
GSK1265744 Pharmacokinetics in Plasma and Tissue After Single-Dose Long-Acting Injectable Administration in Healthy Subjects
William Spreen et al.
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES (2014)
Pharmacokinetics, Safety, and Monotherapy Antiviral Activity of GSK1265744, an HIV Integrase Strand Transfer Inhibitor
W. Spreen et al.
HIV CLINICAL TRIALS (2013)
Share Paper
